Thanatophoric dwarfism (TD) is a sporadic lethal skeletal dysplasia with micromelic shortening of the limbs, macrocephaly, platyspondyly and reduced thoracic cavity. In the most common subtype (TD1), femurs are curved, while in TD2, straight femurs are associated with cloverleaf skull. Mutations in the fibroblast growth factor receptor 3 (FGFR3) gene were identified in both subtypes. While TD2 was accounted for by a single recurrent mutation in the tyrosine kinase 2 domain, TD1 resulted from either stop codon mutations or missense mutations in the extracellular domain of the gene. Here, we report the identification of FGFR3 mutations in 25/26 TD cases. Two novel missense mutations (Y373C and G370C) were detected in 8/26 and 1/26 TD1 cases respectively. Both mutations created cysteine residues in the juxta extramembrane domain of the receptor. Sixteen cases carried the previously reported R248C (9/26 cases), S249C (2/26 cases) or stop codon FGFR3 mutations (5/26 cases). Our results suggest that TD1 is a genetically homogeneous condition and give additional support to the view that newly created cysteine residues in the extracellular domain of the protein play a key role in the severity of the disease.
INTRODUCTION
Thanatophoric dwarfism (TD) is a sporadic neonatal chondrodysplasia causing severe shortening of the limbs with macrocephaly, narrow thorax and short ribs. Femurs and humeri are usually curved (TD1) but the frequent association of straight femurs with cloverleaf skull has led to the delineation of TD2 (1) . The two clinical subtypes have been recently ascribed to mutations in the fibroblast growth factor receptor 3 (FGFR3) gene (2,3) which also accounts for achondroplasia (ACH; 4,5) and hypochondroplasia (HCH; 6). Thus ACH, HCH, TD1 and TD2 are allelic disorders at the FGFR3 locus. Yet, while ACH is largely accounted for by one single mutation in the transmembrane domain, TD1 has been shown to result from either stop codon mutations or missense mutations in the linker region between immunoglobulin-like domains of the protein (Ig II-III; 2,3). Interestingly, all missense mutations hitherto reported in TD1 created unpaired cysteine residues in the extracellular domain of the protein (7) .
Taking advantage of a large series of TD patients, we report here two novel missense mutations, creating unpaired cysteine residues in the extracellular domain of the receptor in 9/26 TD1 patients, which give support to the view that newly created cysteine residues play a major role in the severity of the disease.
RESULTS

De novo mutations in FGFR3 causing TD1
Exon numbering was based on the intron/exon organization of the mouse Fgfr3 gene (8) . An abnormal single strand conformation polymorphism (SSCP) pattern of migration of amplified FGFR3 exon 10 was observed in 8/26 TD1 patients (30%, Fig. 1a ). Sequence analysis revealed an A to G transition at nt 1118 of the coding sequence (Fig. 1b) , changing a tyrosine into a cysteine in the juxta extramembrane domain of the receptor (Y373C). In 1/26 patients (4%), a G to T transversion at nt 1108 changed a glycine into a cysteine in the same domain of the protein (G370C, Fig.  1b ). These base changes were absent in 60 normal individuals (not shown). The previously reported R248C and S249C mutations were found in 9/26 (35%) and 2/26 (8%) TD1 patients respectively in our series. Finally, the stop codon mutations (J807G, J807R and J807C) originally described by Rousseau et al. (2) were found in 5/26 TD1 patients (20%). One TD1 patient had no detectable FGFR3 mutation and the K650E mutation, previously detected in the tyrosine kinase II (TKII) domain in TD2, was not detected in our series, a feature which is consistent with the diagnosis of TD1 in all our cases. The summary of TD mutations hitherto recognized is presented in Table 1 .
Radiological and histological features
Comparison of radiographs between TD1 patients carrying four different mutations failed to demonstrate direct correlation between radiological features and the position of the mutations. Histological sections showed short and disorganized chondrocyte columns, lateral overgrowth of bones with abnormal ossifying mesenchymal tissue (fibrous bands) which disrupted the growth plate whatever the disease-causing mutation (Fig. 2 ). Yet, in three cases, mutations in the linker region between Ig loops II and III (R248C and S249C) apparently produced the most severe disruption of the growth plate with an abnormal line of ossification and almost no chondrocyte columns (Fig. 2b) .
DISCUSSION
The present study shows that three missense mutations in the FGFR3 gene accounted for 73% of all TD1 cases in our series (Y373C, R248C, S249C), the other 23% being accounted for by stop codon mutations (2) and one rare mutation at this locus (G370C). Although no FGFR3 mutation was found in one case, TD1 is likely to be a clinically and genetically homogeneous condition at the FGFR3 locus.
Most interestingly, all missense mutations hitherto reported in TD1 created cysteine residues and all of them were located in the extracellular domain of the receptor. The newly created cysteine residues may allow disulfide bonds to form between the extracellular domains of the mutant monomers, thus inducing a constitutive activation of the receptor which requires dimerization for signal transduction (9) . Such a ligand-independent activation via formation of disulfide-linked dimers has been previously demonstrated in the erythropoietin (10) and the epidermal growth factor receptor (EGFR; 11). By contrast, it is important to realize that mutations of the transmembrane domain resulted in a milder phenotype, ACH, despite the close vicinity of the Y373C TD1 mutation and the G375C ACH mutation (12, 13) . Since an unpaired cysteine residue is unlikely to create a disulfide bond in the transmembrane domain, it probably interferes with α helix stability of this hydrophobic region as hypothesized for the common G380R ACH mutation. Thus, the question of whether or not a constitutive activation of the receptor occurs in ACH is open to debate. As far as genotype-phenotype correlations are concerned, no substantial X-ray differences among TD1 patients were noted, regardless of the location of the mutation in the FGFR3 gene. Similarly, no striking histological differences were visible, although the adjacent R248C and S249C mutations might have more deleterious consequences on the growth plate organization. Whether these particular mutations were fortuitously associated with severe TD1 is questionable and requires more cases for confirmation.
Gain and loss of cysteine residues have been reported in the extracellular domain (third Ig loop) of another fibroblast growth factor receptor, FGFR2, and resulted in craniosynostotic syndromes including Crouzon, Jackson-Weiss and Pfeiffer syndromes (14) (15) (16) (17) . Conformational changes in the Ig loop due to disruption of normal disulfide bonds between highly conserved residues are likely to either alter ligand binding capacities or mimic ligand binding, thus inducing receptor activation as observed in TD1. Further experiments using cells expressing mutant receptors in the presence of appropriate ligands will hopefully elucidate the TD-causing mechanisms.
MATERIALS AND METHODS
Genomic DNA was isolated from cultured skin fibroblasts and frozen tissue samples according to standard procedures.
Exon 10 of FGFR3 which encodes the transmembrane domain and its flanking regions was amplified by using the following primers: 5′ GCCGAGGAGGAGCTGGTGGAGGCT 3′ (forward) and 5′ CTTGAGCGGGAAGCGGGAGATCTTG 3′ (reverse). PCR amplification (annealing temperature of 60_C for 30 cycles, 5% DMSO) generated a 186 bp fragment. For SSCP analysis, PCR was carried out in the presence of [ 33 P]dCTP (0.1 µl/50 µl). Labeled PCR products were denatured then loaded on hydrophobic MDE gels as recommended by the manufacturer (Bioprobe systems) and run in 0.6× TBE buffer at 250 V for 16 h. Gels were dried and autoradiographed. Amplification of exon 7 (8) which encodes the linker region between Ig II and Ig III loops was achieved by using a two-step PCR protocol using primers and conditions previously described by Tavormina et al. (7) (55 bp fragment).
PCR products were purified on Nu-Sieve agarose gels and sequenced by using the fluorescent dideoxy-terminator method on an automated DNA sequencer (Applied Biosystems). To detect the C742T transition in exon 7, the 55 bp fragment was digested with BsiHKAI (New England Biolabs) as recommended by the manufacturer, then run on a 15% polyacrylamide gel. Cleavage into two fragments of 26 and 29 bp respectively was observed when the mutation was present. The C746G transversion created a new BsoFI site which cleaved the 55 bp PCR product into two subfragments of 26 and 29 bp respectively. The stop codon mutations J807G and J807R at nucleotide 2416 (T!G and T!A) abolished an MaeII restriction site while the J807C substitution at nucleotide 2418 (transversion A!T) created an AflIII restriction site.
